Company Overview and News

0
Coromandel International Limited - Investor Presentation

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

0
Coromandel International Limited - Resignation

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

0
Coromandel International Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

0
Coromandel International Limited - Allotment of ESOP/ESPS

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

0
Coromandel International Limited - Financial Results Updates

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

24
RIL, ICICI Bank, HDFC lift Sensex 166 pts; Nifty ends above 10,600 for 1st time since Feb 5

2018-04-24 moneycontrol
The market maintained its gradual uptrend despite consistent increase in crude oil prices, as investors continued to focus on corporate earnings especially after stable numbers announced so far. Positive Asian and European cues also aided sentiment.
HINDCOPPER 500325 RELIANCE HCTHY TCHQY 532978 532712 532755 500470 RCOM 506395 RIGD 532281 RLNIY 500111 YESBANK RELCAPITAL IBN 513599 532648 YYBKY COROMANDEL TECHM ICICIBANK BAJAJFINSV TTST TATASTEEL TATLY 532174 HCLTECH

0
Coromandel International Limited - Financial Result Updates

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

0
Coromandel International Limited - Dividend

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

9
Bharti Airtel, IDFC Bank, GIC Housing results

2018-04-23 thehindubusinessline
Over two dozen companies will declare their results for the quarter and year-ended March 2018 on Tuesday. Among these are Bharti Airtel, Bharat Immunological, Coromandel International, DCM Shriram, GIC Housing, Hindustan Urban Infra, IDFC Bank, ICICI Pru Life Insurance, India Grid, Network18, Oberoi Realty, Persistent Sys, Pioneer Distilleries, Raymond, Supreme Petro, TRF, TV18 Broadcast, Tinplate, Tejas Networks and Zensar Technologies.
PIONDIST 533273 531879 532800 BHRQY COROMANDEL 539437 ZENSARTECH 532454 504067 OBZIY 506395 OBEROIRLTY IDFCBANK HDB 500180 HDFCBANK DCMSHRIRAM TV18BRDCST BHARTIARTL 523367

0
Coromandel International Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-04-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506395 COROMANDEL

27
Market Live: Sensex, Nifty trade lower; all sectoral indices in red except FMCG

2018-04-17 moneycontrol
12:42 pm Market Update: The market is trading mildly lower amid consolidation, after rising in previous 8 consecutive sessions, as investors look for more corporate earnings due over next one and half months.
IOC ORCHIDPHAR 533271 ASHOKA 532712 532832 GLKQY 500470 532187 RCOM 506395 TATASPONGE HDFCBANK BJJQY 500570 500031 TATAMOTORS 500033 500034 GLENMARK 513010 INDUSINDBK FORCEMOT 530965 COROMANDEL 532843 BAJFINANCE TTST 524372 532296 TATASTEEL FORTIS TATLY HDB 500180 IBREALEST BAJAJELEC TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...